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A B S T R A C T
OBJECTIVE: Nine out of ten tuberculosis deaths occur in tuberculosis-burdened countries, particularly Sub
Saharan Africa. In these setting mortality has not been fully described. We describe the magnitude and
pattern of TB mortality in Tanzania.
METHODS: A multicenter prospective cohort study was conducted among HIV infected and uninfected
pulmonary tuberculosis patients from time of anti-TB treatment initiation to completion. Patients were
censored at the time of treatment completion, or at their last visit for those who did not complete TB
treatment. Kaplan-Meier curves were used to estimate time to death; cox proportional hazards model
was used to examine risk factors for mortality.
RESULTS: A total of 58 deaths out of 1696 patients (3.4%) occurred, two thirds (n = 39) during the ﬁrst two
months of treatment. Compared to HIV un-infected TB patients, mortality risk for TB/HIV co-infected
patients was least when antiretroviral therapy (ART) was initiated after 14 days of anti-TB (RR = 3.55; 95%
CI: 1.44, 8.73 p < 0.0001) and highest when ART was initiated 90 days or less prior to anti-TB and within
the ﬁrst 14 days of anti-TB therapy (RR = 10; 95% CI: 3.28, 30.54; p < 0.0001).
CONCLUSION: Meticulously planned and supervised antiretroviral therapy reduces mortality among TB/
HIV patients. Among patients with TB/HIV naïve of ART, withholding ART until the third week of anti-
tuberculosis therapy will likely reduce TB mortality in Tanzania. Patients on ART and later develop
tuberculosis should be closely monitored.
© 2017 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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About 1.5 million tuberculosis (TB) deaths occurred worldwide
in 2014, with nine of ten of the deaths happening in Sub Saharan
Africa (SSA) and South East Asia.1 Tanzania reported 65,732 TB
cases of all forms (smear positive, smear negative and
re-treatment) in 2013.2 About four percent (1048) of newly
diagnosed smear positive PTB patients died.2 HIV co-infection is a
major driver of TB in Tanzania2–4 while multi drug resistance is less
frequently encountered.5,6
TB and HIV co-infection complicates management of both
diseases. Certainly, antiretroviral (ART) has tremendously
improved survival of patients with TB/HIV.7–10 Consequently
earlier initiation of ART is recommended among patients with
TB/HIV confection.11 On the other hand, clinicians need to be aware
that beneﬁts of initiation of ART at HIV diagnosis presents yet other
challenges including increased risk for immune reconstitution
inﬂammatory syndrome (IRIS) among those with sub clinical
TB.12,13 TB/IRIS is a well-recognized phenomenon which occurs
within three months (90 days) of initiating ART.13
Few studies have reported mortality among TB patients in
Eastern SSA.14,15 As a result, global TB mortality estimates are based
on surveys and surveillance systems in developed countries and a
few high burden countries.16 This might not only underestimate
the burden of TB mortality but also reﬂect a poor understanding of
the associated risk factors. With the universal HIV “test and treat”
policy there is need to disentangle mortality risks relative to timing
of ART and anti-TB therapy. We undertook this study to determine
the burden and risk factors for TB mortality among HIV infected
and uninfected TB patients initiating anti-TB treatment in Dar es
Salaam, we also explore mortality risks with respect to ART
initiation relative to initiation of anti-TB therapy.
Methodology
Design and Setting
This study was part of a multi-center prospective observational
study conducted in Dar es Salaam city, Tanzania between 2010 and
2011, as published previously.3
Study population
Eligibility included; age (15 years or above), conﬁrmed
pulmonary TB (at least one sputum specimen positive for acid
fast bacilli (AFB)), initiating TB therapy in one of the 14 selected
study sites. Patients who were previously treated with anti-TB
drugs, or who intended to move out of Dar es Salaam before
completing TB therapy were excluded. Study clinicians recruited
consenting patients consecutively until the desired sample size
was attained. Direct observed therapy (DOT) with isoniazid,
rifampicin, ethambutol and pyrazinamide was instituted daily
according to the national TB treatment policy for six months.
According to Tanzanian guidelines, newly HIV diagnosed patients
within TB treatment services are offered ART as soon as they
tolerated TB drugs, preferably within 2–8 weeks of initiating TB
treatment, however, patient with CD4 < 50cells/mL are initiated
ART within two weeks of anti-TB.17Study procedures
Data were collected at three time points, day one, at two and
ﬁve months of TB treatment, coinciding with patient regular clinic
appointments as stipulated in the National TB guidelines.17 On day
one, the attending clinicians obtained demographic characteristics
from patients, and performed clinical evaluation concurrently with
routine care. An additional sputum specimen was collected for
culture and anti-TB drug sensitivity testing (DST). After two and
ﬁve months of TB treatment, sputum specimens were collected
and re-examined for AFB and vital status was also established.
Patients missing clinic visits were followed by telephone calls or
home visits by trackers. Some patients who missed their visits
moved to different locations and did not respond to telephone
calls, they are reported missing in this report. Heath care trackers
or patients’ treatment supervisors reported events of death, which
were then recorded on patients’ ﬁles and clinic TB register. Other
missing information was collected from HIV database using unique
HIV identiﬁer recorded on patients’ TB card. The vital registration
in the country does not allow for linkage between clinic and death
records.
Laboratory tests
The following tests were employed; sputum culture for M.tb
and drug susceptibility testing (DST) using Mycobacteria Growth
Indicator Tube (MGIT)  (Beckton-Dickinson) or Löwenstein
Jensen (LJ) medium. HIV infection followed the National HIV
screening algorithm.18 serial testing with DetermineTM HIV-1/2
(Inverness Medical Japan Co. Ltd, Japan) and Uni-GoldTM HIV-1/2
(Trinity Biotech, Wicklow, Ireland). Complete blood count (CBC)
was performed using the ACT5 DIFF hematology analyzer
according to the instructions of the manufacturer (Beckman
Coulter, Miami, Florida).
Data collection, management and analysis
Patients demographic, clinical and laboratory information were
recorded in case record forms by the study clinicians and
laboratory personnel, respectively. Information on ART use was
obtained from the clinic registers. Data were double entered into
Epi6 database by trained data clerks. SAS version 9.3 (SAS Institute,
Cary, NC) statistical software was used for statistical analysis.
Categorical data were summarized using proportions, and these
were compared using the Chi square test. Kaplan-Meier curves
were used to estimate the cumulative incidence of death. The
associations between various patient characteristics with mortali-
ty were examined using the Cox proportional hazards model with
time since the initiation of anti-TB therapy as the time scale.
Patients were censored at the end of study if they were event free
or at their last visit for those who did not complete TB treatment.
Relative risks (RRs; hazard ratios), 95% conﬁdence intervals (CIs),
and corresponding p values were obtained from the models
adjusting for potential confounders. The criterion for signiﬁcance
for all the analyses was a P value <0.05 and all p values were two-
tailed.
Outcome of interest is all cause mortality, as deﬁned by WHO
any death occurring during TB therapy is regarded as TB death.1
The explanatory variable of interest was HIV and timing of ART
relative to initiation of anti-TB therapy as a compound variable
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the control/reference group. Bearing in mind the risk of TB/IRIS
within 3 months of ART, we separated TB/HIV patients on ART
before anti-TB therapy into two groups: (Category 2), HIV infected
on ART more than 90 days before initiating anti-TB, (Category 3),
HIV infected and ART initiated 90 days or less prior to anti-TB
initiation. Category 3 also include patients who initiated ART
within 14 days of initiating anti-TB also; Category 4 are patients
who initiated ART after 14 days of anti-TB therapy; and lastly
category 5 are HIV/TB co-infected patients who did not have ART
throughout the entire duration of their observation.
Other possible confounding variables included in the multivar-
iate analyses (MVA) models were variable with known association
with TB mortality or were signiﬁcantly associated with mortality at
P<0.20 in univariate analyses. Therefore, multivariate estimates
were adjusted for age (15-<30, 30-50, and >50), sex (male vs
female), median monthly income in USD (100, <100), illicit
substance use (never, vs current or past),, resistance to INH or
rifampicin (no vs yes). The missing indicator method was used for
missing data in all categorical covariates.
Ethical considerations
Patients provided written informed consent. Minors assented
to participate in the study before guardians/parents signed consent
forms on their behalf. The research protocol was approved by
Muhimbili University of Health and Allied Sciences (MUHAS)
ethical review board (Ref. No. MU/DRP/AEC/Vol.XIII/2008). Hos-
pitals and Municipals management teams granted permits to
conduct the study. Patients with multidrug-resistant TB (MDR-TB)
were put on second line therapy as soon as result became available.Table 1
Baseline characteristics of Pulmonary TB Patients receiving anti-tuberculos
Characteristics 
Age (years) 
15-29 
30-50 
>50 
Sex 
Male 
Female 
Income/month (USD) 
100 
<100 
Cigarette smoking 
Never 
Current or past 
Alcohol use 
Never 
Current or past 
Illicit drug use 
Never 
Current or past 
HIV infection status
HIV uninfected 
HIV infected 
Timing of antiretroviral initiation in respect to initiation of anti-TB thera
>90 days prior to anti-TB started 
90 days prior to anti-TB up to 14 days of starting anti-TB 
>14 days post anti-TB initiation 
No ART at any time during anti-TB 
Anemiaa
No 
Yes 
Isoniazid or rifampicin resistance 
No 
Yes 
a Hemoglobin <12 g/dl for women and <13 g/dl for men; ART = AntiretroviraMono drug resistance was treated on case by case in combination
with clinical response and smear conversion results.
RESULTS
During the study period 1805 patients were recruited, of these
109 (6%) were excluded, due to missing; outcome status or survival
time (88) or HIV status (10) or age (11). This study reports analysis
of a total of 1696 patients who started treatment at the selected
facilities. Patients included in this analysis (n = 1696) and those
excluded (n = 109) did not differ with respect to age (p = 0.76),
education (p = 0.20), income (p = 0.41), hemoglobin (p = 0.95), HIV
status (p = 0.55), ART use (p = 0.21) resistance to rifampicin or INH
(p = 0.85), data not shown here. However, excluded patients were
more likely to be males (80% Vs 67%; p < 0.01) and have higher
proportion using illicit drugs (15% vs 6% p < 0.01).
Table 1 provides baseline demographic and clinical character-
istics of the study population. The patients were relatively young,
40% aged less than thirty years; two thirds were males. The median
monthly income was approximately 100 US dollars (Table 1).
Alcohol, cigarette smoking and use of addictive drugs were not
uncommon in this study population. Twenty-nine (3.3%) of the
patients who had anti-sensitivity test had resistance to either
isoniazid or rifampicin. Thirty percent of the patients (514) were
infected with HIV, of whom 285 (50%) were not on any ART until
end of their follow up. About one in ten of patients (n = 49) with TB/
HIV co-infection were on ART more than 90 day before initiation of
TB therapy, eight percent (n = 39) initiated ART within 90 before
anti-TB commenced or within 14 days after commencement of
anti-TB. Majority of those on ART during anti-TB therapy initiated
ART after 14 days of anti-TB therapy (n = 141; 27%). (Table 1)is treatment in Dar es Salaam, Tanzania.
Missing n (%) N %
0
682 40.21
868 51.18
146 8.61
0
1138 67.10
558 32.90
362 (21.34)
746 55.92
588 44.08
24 (1.42)
1223 73.15
449 26.85
37 (2.18)
1064 64.14
595 35.86
56 (3.30)
1542 94.02
98 5.98
0 1182 69.69
514 30.31
py
0 49 9.53
39 7.89
141 27.43
285 50.19
234 (13.80)
202 13.82
1260 86.18
816 (48.11)
851 96.70
29 3.30
l status.
Table 2
Crude mortality pattern in according to HIV infection and antiretroviral status of the patients.
No of deaths No at risk Crude mortality risk Median time to death in days (IQR)*
TB only 17 1182 1.4 46 (32,62)
TB/HIV; ART >90 days prior to anti-TB 5 49 10.2 79 (33,96)
TB/HIV; ART 90 days prior to anti-TB to 14 days after ART 4 39 10.3 56 (28, 72)
TB/HIV; ART >14 days post anti-TB 7 141 5.0 52 (45,89)
TB/HIV; No ART 25 285 8.8 37 (26,59)
Total 58 1696 3.4 46 (30,72)
* IQR = interquartile range.
Table 3
Factors associated with mortality among Pulmonary TB Patients receiving treatment in Dar es Salaam, Tanzania.
Unadjusted Adjusted
No of
deaths
HR 95%
CI
P HR 95%
CI
P
HIV infection and ART use <0.001 <0.001
HIV uninfected 17/1182 1.00 1.00
HIV infected; ART >90 days prior to anti-TB therapy 5/49 7.00 2.58 18.96 8.26 2.89 23.64
HIV infected; ART 90 days prior to anti-TB and within 14 days of anti-TB therapy
initiation
4/39 7.55 2.54 22.44 10.00 3.28 30.54
HIV infected; ART >14 days post anti-TB therapy initiation 7/141 3.43 1.42 8.26 3.55 1.44 8.73
HIV infected; No ART at any time during anti-TB therapy 25/285 6.34 3.42 11.74 6.46 3.41 12.24
Isoniazid or rifampicin resistance 0.01 0.02
No 21/851 1.00 1.00
Yes 3/29 4.50 1.34 15.10 4.24 1.24 14.48
Age (years) 0.08 0.60
15-29 16/682 1.00 1.00
30-50 36/868 1.76 0.98 3.17 1.11 0.60 2.06
>50 6/146 1.74 0.68 4.45 1.29 0.49 3.40
Sex 0.95 0.20
Male 39/1138 1.00 1.00
Female 19/558 0.98 0.57 1.70 1.46 0.82 2.62
Monthly income (USD) 0.07 0.03
 100 21/746 1.00 1.00
<100 28/588 1.70 0.97 3.00 1.91 1.07 3.39
Illicit substance use 0.09 0.09
Never 48/1542 1.00 1.00
Current or past 6/98 2.06 0.88 4.82 2.14 0.90 5.12
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duration. A total of 58 deaths occurred among the patients with TB,
equivalent to a cumulative mortality incidence of 3.4% within six
months of follow up. In the worst scenario if all 109 patients
excluded in this study are considered dead then the maximum
mortality in this cohort would be 9.3%. Patients with TB/HIV co-
infection were more likely to die. However, patients who initiated
ART therapy before anti TB were had highest mortality while
patients who initiated ART after 14 days of anti-TB therapy had
lower mortality (5%). Patients exhibited an accelerated mortality
during the early phase of TB treatment; the overall median time to
death is 46 days. (Table 2)
As shown in Table 3, HIV infection, resistance to INH or
rifampicin and low monthly income; were independent mortality
predictors. Compared to HIV un-infected TB patients mortality riskTable 4
Comparison of patients with TB/HIV according to CD4 and body mass index (BMI).
HIV infected; ART started more than 90 days before starting anti-TB therapy 
HIV infected; ART started 90 days before starting or up to 14 days after starting anti
HIV infected; ART started more than 14 days and up to 180 days after starting anti-T
HIV infected; not on ART at any time or ART initiated more than 180 days after startwas tenfold among TB/HIV co-infected who initiated ART 90 days
or less prior to and within the ﬁrst 14 days of anti-TB therapy.
(RR = 10; 95% CI: 3.28, 30.54; p < 0.0001) while, patients who
initiated ART after 14 days of anti-TB had a threefold mortality risk
(RR = 3.55; 95% CI: 1.44, 8.73 p < 0.0001). Further examination of
categories of TB/HIV co-infected patients is provided in Table 4.
Patients who initiated ART more than 90 days prior to anti-TB had
median CD4+ 263 cell/mL while those who initiated ART after ﬁrst
14 days of anti-TB therapy had the lowest CD4 counts 151 cells/mL.
Patients who were not on ART during the entire period of
observation had relatively higher median CD4+ counts (331 cells/
mL) Table 4.
Patient with TB infected with mycobacteria resistant to INH or
rifampicin had a fourfold increased mortality risk (RR = 4.24; 95%
CI: 1.24, 14.48; p = 0.02). Monthly income lower than 100 USD wasMedian
CD4 (IQR)
Median
BMI (IQR)
263 (181, 422) 18.8 (17.0, 21.5)
-TB therapy 168 (79, 221) 17.4 (15.4, 19.6)
B therapy 151 (69, 220) 18.7 (16.9, 21.2)
ing anti-TB therapy 331 (158, 471) 18.1 (16.5, 20.4)
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(RR = 1.91; 95%CI 1.07, 3.39; P = 0.03) Table 3.
DISCUSSION
This study describes mortality among patients with TB in
general, and TB/HIV co-infected patients, who were on the HIV care
and treatment programme after scale up of ART services in
Tanzania.14 Of particular note, the composition of our current study
population mirrors the most recent reported country’s TB
population; male predominance, young adults being more affected
and almost one third of patients with TB and HIV coinfection.2 To
the best knowledge of the authors, it is the ﬁrst to report mortality
among patients with TB within treatment duration, after wide
spread of ART in the country.14,15
We observed an overall low cumulative mortality incidence of
3.4% among patients with newly diagnosed open TB during the
course of TB treatment. However due to failure to account for 109
patients, the highest mortality possible would be 9.3% if we assume
all missing patients had died. We note a precipitous mortality
within intensive phase of anti-TB therapy. HIV co-infection, ART as
well as resistance to either INHor rifampicin and low income were
associated with increased mortality risk in this cohort.
Mortality rate in our current cohort is similar to that reported
by national cohort, 4% (1048/24,241) of patients with newly
diagnosed smear-positive TB in 2013,2 and is comparatively low
compared with TB-associated mortality rates in high endemic
countries (4-18%) (14-18). These differences could be varying
degrees in drug resistance as well as co-morbidities such as HIV co-
infections, anemia, diabetes mellitus, malignancies and renal
failure, among other reasons,15,19–22 duration of illness as well as
well adherence to TB treatment.23–25 In Tanzania, HIV is main
driver of tuberculosis disease.14,26 Unlike in countries with high
burden of MDR-TB, properly administered ART and anti-TB therapy
would reduce TB/HIV mortality. Further, adherence to anti-TB
therapy is key to a successful treatment program; highly efﬁcient
DOTS system in Tanzania that ensure adherence of 96%27 might
contribute to lower mortality in our setting.
Our results do show that TB/HIV co-infection is a spectrum of
disease that may not be taken as one entity. HIV was an
independent predictor for mortality and ART reduces mortality
among patients with HIV and TB co-infection. These ﬁndings are in
keeping with the ﬁndings of a large South African TB program
showing a 5 times increased case fatality rate among TB/HIV
positive patients compared to HIV-negative patients with TB,28
and is consistent with the observed beneﬁts of early initiation of
ART in decreasing TB disease events29,30 and deaths.7–10 Two thirds
of the deaths in this cohort occurred during the intensive phase of
anti-TB treatment, which is in keeping with the ﬁndings of
previous studies, being (24-26), and could be due to treatment
complications linked to immune reconstitution inﬂammatory
syndrome.31 Indeed, in our cohort, the highest mortality risk was
among patients treated with ART 90 days before anti-TB therapy
and within the ﬁrst 14 days of anti-TB therapy. TB/IRIS is a
recognized phenomenon within this period.13 Drug to drug
interaction might have complicated treatment and result in fatal
side effect, evaluation of mortality causes would be advantageous
to this end. Further evaluation of factors associated with death
during the intensive TB treatment phase is essential.
The highest mortality among patients with TB/HIV co-infection
occurred among those who initiated ART 90 or less days before
anti-TB drugs or within the ﬁrst 14 days of anti-TB therapy. This
category of patients are likely to have had an advanced HIV disease
at the time of presentation as demonstrated with their median
body mass index (BMI) 17.4 kg/m2. Secondly, due to their low
CD4 + levels (168 cells/mL), these patients may have or had sub-clinical TB, which was unmasked and associated with the recovery
of T-cell function.32–34 Severe immune deﬁciency has been
associated with increased risk of both poor immunological
recovery, TB/IRIS and mortality associated with TR/IRIS.35,36 The
other category of patients who have been on ART well in advance of
diagnosis and treatment with anti-TB therapy are clearly not well
suppressed (CD4+ 268 cells/mL) as shown in the result section. In
addition, three out of the ﬁve patients in this category had CD4 less
than 200 cells/mL. Treatment failure, due to prior ART adherence or
drug resistance is speculated as cause of mortality in this group.
Data on drug resistance pattern and viral load could assist in this
matter. On the other hand, postponing ART among TB/HIV+
individuals, even when CD4 level were relatively high (331 cells/
mL), was detrimental for the category ﬁve patients, i.e TB+/HIV+
patients who did not have ART until they either died or completed
the anti-TB drug treatment regiment. Together our results and
previous reports7,10 lends support that concomitant ART and anti-
TB treatment signiﬁcantly reduced mortality when properly
instituted. Among ART naïve TB patients, withholding ART for
the ﬁrst until after ﬁrst two week of TB therapy would be prudent.
The main weakness of this study is the exclusion of 109 (6%) of
the study participants due to missing outcomes or exposure of
interest. However we found no substantial difference between
excluded and included patients except for sex and illicit drug use. It
is likely that mortality estimates, presented in this report, are
underestimation since both male sex and illicit drug use are known
factors associated with poor TB outcome. Should this be the case
the true mortality would between 3.4% and 9.3% at its highest.
Nonetheless our study has several strengths. First, it was
conducted in the region with highest TB notiﬁcations in Tanzania.
Second, mortality and HIV rates in our population mirrors that of
the national cohort2 and in addition to reporting mortality were
able to examine associated risk factors among patients with TB and
HIV co-infection or without makes our study very unique. We hope
this strength makes it possible to generalizable ﬁndings from this
study into working policies in Tanzania and other countries within
SSA with similar TB dynamics.
In conclusion, despite low overall mortality among open TB cases
in Dar es Salaam, most of the deaths occur during the early during
anti-tuberculosis treatment. Delay of ART initiation until third week
of anti-TB therapy is recommended for ART naïve TB/HIV co-infected
patients. This study therefore supports the WHO recommendation
for “test andtreat” HIV infectedindividualsdespite CD4+ countwhile
careful monitoring their immunological recovery.
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